At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 62 enrolled
Drug / intervention
E7130 +1 moredrug
Likely dose
E7130 25 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of E7130 in Subjects With Solid Tumor
In Brief
A Phase 1 clinical trial evaluating E7130 for Solid Tumors. Completed, enrolled 62 participants across 9 sites.
Detailed Summary
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedFeb 2018
Primary CompletionDec 2024
TodayJul 2026
First PostedFeb 23, 2018
Enrollment StartFeb 5, 2018
Primary CompletionDec 27, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 8.4 years ago
Interventions
E7130drug
Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
E7130drug
Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.